ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0435

Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071

Parvathi Kumar1, Pamela Hair1, Ulrich Thienel1, Kenji Cunnion1, Neel Krishna2 and Christos Gabriel3, 1ReAlta Life Sciences Inc, Norfolk, VA, 2ReAlta Life Sciences Inc., Norfolk, VA, 3Children's Hospital of The King's Daughters, Norfolk

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, inhibitor, MPO, NETosis, RLS-0071

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Anti-neutrophil cytoplasm antibodies (ANCA) are immunoglobulin G (IgG) autoantibodies directed against constituents of primary neutrophil granules (Davies, Moran et al. 1982). There is strong clinical, in vitro and in vivo evidence to suggest that ANCAs are pathogenic (Jennette and Falk 2014) causing pauci-immune necrotizing and crescentic glomerulonephritis (NCGN) and systemic small vessel vasculitis. One of the major target antigens for ANCA is myeloperoxidase (MPO) (Schreiber, Xiao et al. 2006). Both MPO and the reactive oxidants it generates have been implicated as participating in tissue injury in a large number of inflammatory conditions (Nicholls and Hazen 2005). There is no available information as to activity of circulating MPO in individuals with AAV although there is limited evidence that MPO-ANCAs, extracellular MPO, and in situ immune complexes composed of MPO and anti-MPO antibodies may have an important role in the pathogenesis of glomerular capillary injury in MPO-ANCA associated vasculitis (Arimura, Kawashima et al. 2013). Additionally, MPO can stimulate Neutrophil Extracellular Trap (NET) formation which exacerbate inflammation contributing to the dysfunction in AAV as evidenced by NETs found on kidney biopsy specimens from patients with small vessel vasculitis (Kessenbrock, Krumbholz et al. 2009). ReAlta’s lead compound, RLS-0071, is a PEGylated peptide which has exhibits inhibition of MPO activity in animal models and ex vivo and demonstrates inhibition of MPO activity on an equimolar basis to the prototypical MPO inhibitor ABAH (4-aminobenzoic acid hydride). RLS-0071 also inhibits neutrophil mediated NETosis in vitro and in vivo (Hair, Enos et al. 2019, Enos, Hair et al. 2020).

Methods: To better understand the role of MPO in ANCA associated pathophysiology, we conducted pilot analyses measuring MPO activity in plasma samples acquired commercially from individuals with known ANCA. AI (Antibody Index) units were available for each sample which represents a composite score of anti- MPO, anti- PR3 and anti- GBM antibody titers. MPO activity was measured using a TMB oxidation assay in which absorbance was measured a 450nm in a plate reader. The efficacy of RLS-0071 to inhibit MPO activity was evaluated in this assay.

Results: MPO activity as measured at 450nm absorbance ranged from 0 to 3.105. A positive correlation between MPO activity with the AI units in patient samples was observed (R2= 0.76; p=0.0046). Addition of increasing concentrations of RLS-0071 to the patient samples showed a dose dependent decrease in MPO activity to a similar level as that observed with the MPO inhibitor ABAH.

Conclusion: In this pilot study, plasma from patients with ANCA demonstrated a wide range of MPO activity with the AI units trending with plasma MPO activity. Additionally, RLS-0071 inhibited MPO activity in plasma acquired from individuals with ANCA associated pathophysiology. Future studies will focus on elucidating relationships between MPO activity, MPO quantity, free plasma DNA as a surrogate measurement of NETs and anti-MPO titers.

Positive correlation between MPO activity with AI (composite score of anti- MPO, anti- PR3 and anti- GBM antibody titers)

Dose responsive decrease in MPO activity by RLS-0071 comparable to prototypical MPO inhibitor ABAH


Disclosures: P. Kumar, ReAlta Life Sciences Inc, 3, ReAlta Life Sciences Inc, 2; P. Hair, ReAlta Life Sciences Inc, 3; U. Thienel, ReAlta Life Sciences Inc, 3; K. Cunnion, ReAlta Life Sciences Inc, 3, 4; N. Krishna, ReAlta Life Sciences Inc, 3; C. Gabriel, None.

To cite this abstract in AMA style:

Kumar P, Hair P, Thienel U, Cunnion K, Krishna N, Gabriel C. Myeloperoxidase Activity in Individuals with Antineutrophil Cytoplasmic Antibodies (ANCA) Can Be Inhibited by RLS-0071 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/myeloperoxidase-activity-in-individuals-with-antineutrophil-cytoplasmic-antibodies-anca-can-be-inhibited-by-rls-0071/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myeloperoxidase-activity-in-individuals-with-antineutrophil-cytoplasmic-antibodies-anca-can-be-inhibited-by-rls-0071/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology